Private Advisor Group’s Unity Biotechnology UBX Stock Holding History

Private Advisor Group’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14	Closed	-$1K	–	3306
2020 Q2	$1K	Buy	+14	New	+$1.04K	﹤0.01%	3763

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Private Advisor Group's UBX Position: Q3 2020 in Review

Private Advisor Group sold out of Unity Biotechnology (UBX) in Q3 2020, closing a stake of 14 shares — an estimated $1K sold.

Private Advisor Group first reported a position in UBX in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 79 funds tracked by Wall St. Rank hold UBX as of Q3 2020.

Private Advisor Group reported no remaining Unity Biotechnology position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 14 Unity Biotechnology shares in Q3 2020, an estimated $1K.
Private Advisor Group first reported a position in Unity Biotechnology in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Unity Biotechnology position peaked at $1K in Q2 2020.
79 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.